Blue Trust Inc. Boosts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Blue Trust Inc. boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 38.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,981 shares of the medical equipment provider’s stock after acquiring an additional 547 shares during the quarter. Blue Trust Inc.’s holdings in Lantheus were worth $177,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after buying an additional 32,551 shares during the period. Moloney Securities Asset Management LLC purchased a new stake in Lantheus in the 3rd quarter worth $1,066,000. Massachusetts Financial Services Co. MA acquired a new position in Lantheus during the third quarter worth $25,955,000. Van ECK Associates Corp lifted its holdings in Lantheus by 58.6% during the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after purchasing an additional 21,604 shares in the last quarter. Finally, Empirical Asset Management LLC acquired a new stake in shares of Lantheus in the fourth quarter valued at about $323,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. JMP Securities restated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial restated a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Insider Buying and Selling

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.10% of the company’s stock.

Lantheus Price Performance

LNTH stock opened at $91.80 on Wednesday. The business’s 50-day moving average is $92.07 and its two-hundred day moving average is $99.16. The firm has a market capitalization of $6.38 billion, a P/E ratio of 15.27 and a beta of 0.44. Lantheus Holdings, Inc. has a 1 year low of $52.96 and a 1 year high of $126.89.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.